Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Hereditary primary lateral sclerosis and progressive nonfluent aphasia.

Gazulla J, Ferrer I, Izquierdo-Alvarez S, Alvarez S, Sánchez-Alcudia R, Bestué-Cardiel M, Seral M, Benavente I, Sierra-Martínez E, Berciano J.

J Neurol. 2019 May;266(5):1079-1090. doi: 10.1007/s00415-019-09235-x. Epub 2019 Mar 5.

PMID:
30834979
2.

Inaugural cognitive decline, late disease onset and novel STUB1 variants in SCAR16.

Gazulla J, Izquierdo-Alvarez S, Sierra-Martínez E, Marta-Moreno ME, Alvarez S.

Neurol Sci. 2018 Dec;39(12):2231-2233. doi: 10.1007/s10072-018-3545-5. Epub 2018 Sep 11. No abstract available.

PMID:
30206723
3.

Myoclonus-dystonia and cerebellar ataxia in association with anti-glutamic acid decarboxylase autoimmunity.

Isern de Val Í, Gazulla J.

Neurologia. 2018 Jul 26. pii: S0213-4853(18)30177-4. doi: 10.1016/j.nrl.2018.05.004. [Epub ahead of print] English, Spanish. No abstract available.

4.

Convexity subarachnoid haemorrhage secondary to hereditary haemorrhagic telangiectasia.

Sancho Saldaña A, Lambea Gil Á, Sánchez Marín B, Gazulla J.

Neurologia. 2018 Jun 10. pii: S0213-4853(18)30155-5. doi: 10.1016/j.nrl.2018.04.005. [Epub ahead of print] English, Spanish. No abstract available.

5.

Cerebellar ataxia, neuropathy, vestibular areflexia syndrome (CANVAS) with chronic cough and preserved muscle stretch reflexes: evidence for selective sparing of afferent Ia fibres.

Infante J, García A, Serrano-Cárdenas KM, González-Aguado R, Gazulla J, de Lucas EM, Berciano J.

J Neurol. 2018 Jun;265(6):1454-1462. doi: 10.1007/s00415-018-8872-1. Epub 2018 Apr 25.

PMID:
29696497
6.

[Myths and evidence on the use of botulinum toxin: neuropharmacology and dystonia].

Garcia-Ruiz PJ, Sanz-Cartagena P, Martinez-Castrillo JC, Ares-Pensado B, Aviles-Olmos I, Blazquez-Estrada M, Fanjul-Arbos S, Garcia-Caldentey J, Gazulla J, Gutierrez-Garcia J, Huete-Anton B, Lucas-Rodenas C, Luquin MR, Martinez-Torres I, Medialdea-Natera P, Mendoza-Rodriguez A, Mir-Rivera P, Posada IJ, Ruiz-Martinez J, Sanchez-Alonso P, Trejo-Gabriel Y Galan JM, Vela L, Pena-Segura JL.

Rev Neurol. 2018 Mar 1;66(5):163-172. Review. Spanish.

7.

Reversible inflammatory neuropathy superimposed on Charcot-Marie-Tooth type 1A disease.

Gazulla J, Almárcegui C, Berciano J.

Neurol Sci. 2018 Apr;39(4):793-794. doi: 10.1007/s10072-017-3195-z. Epub 2017 Nov 21. No abstract available.

PMID:
29164357
8.

Intermediate Charcot-Marie-Tooth disease: an electrophysiological reappraisal and systematic review.

Berciano J, García A, Gallardo E, Peeters K, Pelayo-Negro AL, Álvarez-Paradelo S, Gazulla J, Martínez-Tames M, Infante J, Jordanova A.

J Neurol. 2017 Aug;264(8):1655-1677. doi: 10.1007/s00415-017-8474-3. Epub 2017 Mar 31. Review.

PMID:
28364294
9.

Migralepsy and migraine in the puerperal period.

Gazulla J, Betancourt A, Mata-Gazulla L.

Neurologia. 2018 Apr;33(3):202-204. doi: 10.1016/j.nrl.2016.12.008. Epub 2017 Mar 17. English, Spanish. No abstract available.

10.

Paraparetic Guillain-Barré syndrome: Non-demyelinating reversible conduction failure restricted to the lower limbs.

Gazulla J, Benavente I.

Muscle Nerve. 2017 Jul;56(1):E7. doi: 10.1002/mus.25569. Epub 2017 Mar 21. No abstract available.

PMID:
28073156
11.

Une cause inhabituelle d’hyperCKémie.

Modrego PJ, Gazulla J, Cobo AM, Andoni Urtizberea J.

Med Sci (Paris). 2016 Nov;32 Hors série n°2:12-13. Epub 2016 Nov 21. French. No abstract available.

12.

Aseptic meningitis and anti-β2-glycoprotein 1 antibodies in Sweet syndrome.

Cruz-Velásquez GJ, Pac Sha J, Simal Gil E, Gazulla J.

Neurologia. 2018 Nov - Dec;33(9):620-621. doi: 10.1016/j.nrl.2016.06.001. Epub 2016 Jul 21. English, Spanish. No abstract available.

13.

Ataxia and focal dystonia in Kallmann syndrome.

Hernando-Quintana N, Playán-Usón J, Crespo-Burillo JA, Marín-Cárdenas MÁ, Gazulla J.

Clin Case Rep. 2015 Dec 28;4(2):182-5. doi: 10.1002/ccr3.420. eCollection 2016 Feb.

14.

Sensory Neuronopathy in CANVAS: Cerebellar Ataxia, Neuropathy, and Vestibular Areflexia.

Gazulla J, Pablo-Zaro MJ, Fraile-Rodrigo J, Larrodé P.

Can J Neurol Sci. 2016 Jul;43(4):604-5. doi: 10.1017/cjn.2015.396. Epub 2016 Feb 3. No abstract available.

PMID:
26837948
15.

GABAergic Pharmacotherapy in the Treatment of Motor Disorders of the Central Nervous System.

Gazulla J, Ruiz-Gazulla C, Tintore M.

Curr Pharm Des. 2015;21(34):4989-95. Review.

PMID:
26365142
16.

Multiple-system atrophy.

Gazulla J, Berciano J.

N Engl J Med. 2015 Apr 2;372(14):1374. doi: 10.1056/NEJMc1501657. No abstract available.

PMID:
25830436
17.

Clinical categorization of psychogenic blepharospasm.

Gazulla J, García-Rubio S, Ruiz-Gazulla C, Modrego P.

Parkinsonism Relat Disord. 2015 Mar;21(3):325-6. doi: 10.1016/j.parkreldis.2014.12.005. Epub 2014 Dec 16. No abstract available.

PMID:
25558013
18.

Ataxia of Charlevoix-Saguenay: MR and Clinical Results in Lower-Limb Musculature.

Gazulla J, Mayayo-Sinués E, Benavente I, Modrego PJ, Berciano J.

Can J Neurol Sci. 2014 Jan;41(1):37-41.

PMID:
24384335
19.

[Finding of retinal nerve fiber layer hypertrophy in ataxia of Charlevoix-Saguenay patients].

Garcia-Martin E, Bambo MP, Gazulla J, Larrosa JM, Polo V, Fuertes MI, Fuentes JL, Ferreras A, Pablo LE.

Arch Soc Esp Oftalmol. 2014 May;89(5):207-11. doi: 10.1016/j.oftal.2012.11.009. Epub 2013 Apr 3. Spanish.

PMID:
24269465
20.

Retinal segmentation as noninvasive technique to demonstrate hyperplasia in ataxia of Charlevoix-Saguenay.

Garcia-Martin E, Pablo LE, Gazulla J, Vela A, Larrosa JM, Polo V, Marques ML, Alfaro J.

Invest Ophthalmol Vis Sci. 2013 Oct 29;54(10):7137-42. doi: 10.1167/iovs.13-12726.

PMID:
24114536
21.

The predictive value of the memory impairment screen in patients with subjective memory complaints: a prospective study.

Modrego PJ, Gazulla J.

Prim Care Companion CNS Disord. 2013;15(1). pii: PCC.12m01435. doi: 10.4088/PCC.12m01435. Epub 2013 Jan 31.

22.

Retinal nerve fibre layer thickness in ARSACS: myelination or hypertrophy?

Garcia-Martin E, Pablo LE, Gazulla J, Polo V, Ferreras A, Larrosa JM.

Br J Ophthalmol. 2013 Feb;97(2):238-41. doi: 10.1136/bjophthalmol-2012-302309. Epub 2012 Oct 17. No abstract available.

23.

Syndrome of cerebellar ataxia, neuropathy and vestibular areflexia: diagnosis by caloric vestibular stimulation.

Crespo-Burillo JA, Hernando Quintana N, Fraile Rodrigo J, Gazulla J.

Neurologia. 2013 Nov-Dec;28(9):591-2. doi: 10.1016/j.nrl.2012.06.001. Epub 2012 Aug 11. English, Spanish. No abstract available.

24.

Arterial hypertension induced by interferon beta 1b in a patient with multiple sclerosis.

Modrego PJ, Gazulla J.

Mult Scler. 2012 Nov;18(11):1655-6. doi: 10.1177/1352458512441272. Epub 2012 Mar 14. No abstract available.

PMID:
22419671
25.

Magnetic resonance imaging based clinical research in Alzheimer's disease.

Fayed N, Modrego PJ, Salinas GR, Gazulla J.

J Alzheimers Dis. 2012;31 Suppl 3:S5-18. Review.

PMID:
22233763
26.

New findings in the ataxia of Charlevoix-Saguenay.

Gazulla J, Benavente I, Vela AC, Marín MA, Pablo LE, Tessa A, Barrena MR, Santorelli FM, Nesti C, Modrego P, Tintoré M, Berciano J.

J Neurol. 2012 May;259(5):869-78. doi: 10.1007/s00415-011-6269-5. Epub 2011 Oct 13.

PMID:
21993619
27.

Retinal nerve fiber hypertrophy in ataxia of Charlevoix-Saguenay patients.

Pablo LE, Garcia-Martin E, Gazulla J, Larrosa JM, Ferreras A, Santorelli FM, Benavente I, Vela A, Marin MA.

Mol Vis. 2011;17:1871-6. Epub 2011 Jul 13.

28.

Is the ataxia of Charlevoix-Saguenay a developmental disease?

Gazulla J, Vela AC, Marín MA, Pablo L, Santorelli FM, Benavente I, Modrego P, Tintoré M, Berciano J.

Med Hypotheses. 2011 Sep;77(3):347-52. doi: 10.1016/j.mehy.2011.05.011. Epub 2011 Jun 12.

PMID:
21665375
29.

Sensory neuronopathy in ataxia with oculomotor apraxia type 2.

Gazulla J, Benavente I, López-Fraile IP, Tordesillas C, Modrego P, Alonso I, Pinto-Basto J.

J Neurol Sci. 2010 Nov 15;298(1-2):118-20. doi: 10.1016/j.jns.2010.09.004. Epub 2010 Sep 24.

PMID:
20869730
30.

Ataxia with oculomotor apraxia type 2: clinical, biological and genotype/phenotype correlation study of a cohort of 90 patients.

Anheim M, Monga B, Fleury M, Charles P, Barbot C, Salih M, Delaunoy JP, Fritsch M, Arning L, Synofzik M, Schöls L, Sequeiros J, Goizet C, Marelli C, Le Ber I, Koht J, Gazulla J, De Bleecker J, Mukhtar M, Drouot N, Ali-Pacha L, Benhassine T, Chbicheb M, M'Zahem A, Hamri A, Chabrol B, Pouget J, Murphy R, Watanabe M, Coutinho P, Tazir M, Durr A, Brice A, Tranchant C, Koenig M.

Brain. 2009 Oct;132(Pt 10):2688-98. doi: 10.1093/brain/awp211. Epub 2009 Aug 20.

PMID:
19696032
31.

Sensorimotor neuronopathy in ataxia with oculomotor apraxia type 2.

Gazulla J, Benavente I, López-Fraile IP, Modrego P, Koenig M.

Muscle Nerve. 2009 Sep;40(3):481-5. doi: 10.1002/mus.21328.

PMID:
19618424
32.

Buspirone and serotonin in spinocerebellar ataxia.

Gazulla J, Modrego P.

J Neurol Sci. 2008 May 15;268(1-2):199-200; author reply 200-1. doi: 10.1016/j.jns.2007.12.008. Epub 2008 Jan 28. No abstract available.

PMID:
18222483
33.

Single-blind, placebo-controlled pilot study of pregabalin for ataxia in cortical cerebellar atrophy.

Gazulla J, Benavente I.

Acta Neurol Scand. 2007 Oct;116(4):235-8.

PMID:
17824901
34.

[An update on neurochemistry and pharmacological therapy of the cerebellar ataxias].

Gazulla J.

Rev Neurol. 2007 Jul 1-15;45(1):31-41. Review. Spanish.

35.

[P/Q-type voltage-dependent calcium channels in neurological disease].

Gazulla J, Tintore M.

Neurologia. 2007 Oct;22(8):511-6. Review. Spanish.

PMID:
17573560
36.

The P/Q-type voltage-dependent calcium channel: a therapeutic target in spinocerebellar ataxia type 6.

Gazulla J, Tintoré M.

Acta Neurol Scand. 2007 May;115(5):356-63. Review.

PMID:
17489948
37.

New therapies for ataxia-telangiectasia.

Gazulla J, Benavente I, Sarasa M.

Arch Neurol. 2007 Apr;64(4):607-8; author reply 608-9. No abstract available.

PMID:
17420328
38.

[Adult-onset ataxia-telangiectasia. A clinical and therapeutic observation].

Gazulla J, Benavente I, Sarasa Barrio M.

Neurologia. 2006 Oct;21(8):447-51. Spanish.

PMID:
17013792
40.

[Glutamate and Alzheimer's disease].

Gazulla J, Cavero-Nagore M.

Rev Neurol. 2006 Apr 1-15;42(7):427-32. Review. Spanish.

41.

[Improvements in the symptoms of olivopontocerebellar atrophy with gabapentin].

Gazulla J, Benavente MI.

Rev Neurol. 2005 Mar 1-15;40(5):285-8. Spanish.

42.

Treatment of ataxia in cortical cerebellar atrophy with the GABAergic drug gabapentin. A preliminary study.

Gazulla J, Errea JM, Benavente I, Tordesillas CJ.

Eur Neurol. 2004;52(1):7-11. Epub 2004 Jun 22.

PMID:
15218338
43.

Improvement of ataxia in cortical cerebellar atrophy with the drug gabapentin.

Gazulla J, Errea J, Benavente I, Tordesillas C.

Clin Neuropharmacol. 2003 Sep-Oct;26(5):225-6. No abstract available.

PMID:
14520159
44.

Six mutagenicity assays in exposure biomonitoring of patients receiving carbamazepine for epilepsy or trigeminal neuralgia.

Sinués B, Gazulla J, Bernal ML, Lanuza J, Fanlo A, Saenz MA, Barolome M.

Mutat Res. 1995 Apr;334(2):259-65.

PMID:
7885380
45.

[Complications of Gaucher's disease].

Modrego Pardo PJ, Garzarán G, González N, Baiges JJ, Gazulla J.

Rev Clin Esp. 1992 Oct;191(6):311-3. Spanish.

PMID:
1470721

Supplemental Content

Loading ...
Support Center